Haqq Christopher 4
4 · Atara Biotherapeutics, Inc. · Filed Nov 15, 2018
Insider Transaction Report
Form 4
Haqq Christopher
Chief Medical Officer
Transactions
- Sale
Common Stock
2018-11-15$33.81/sh−775$26,203→ 285,580 total
Holdings
- 17,312(indirect: See footnote)
Common Stock
- 2,688(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.65 to $34.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- [F4]The shares are held by The Havenside Trust, of which the Reporting Person is trustee.